{{Rsnum
|rsid=5760410
|Gene=SPECC1L
|Chromosome=22
|position=24419438
|Orientation=plus
|GMAF=0.4665
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
|Gene_s=SPECC1L-ADORA2A
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 25.2 | 51.4 | 23.4
| HCB | 33.6 | 53.3 | 13.1
| JPT | 42.5 | 45.1 | 12.4
| YRI | 22.6 | 54.1 | 23.3
| ASW | 17.5 | 52.6 | 29.8
| CHB | 33.6 | 53.3 | 13.1
| CHD | 38.0 | 40.7 | 21.3
| GIH | 23.8 | 42.6 | 33.7
| LWK | 28.2 | 57.3 | 14.5
| MEX | 36.2 | 50.0 | 13.8
| MKK | 19.6 | 54.7 | 25.7
| TSI | 23.2 | 54.5 | 22.2
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs5760410
|Name_s=ADORA2A: g.4205975G>A
|Gene_s=CYTSA
|Feature=
|Evidence=PubMed ID:18539621
|Annotation=Risk or phenotype-associated allele: rs5760410 G allele. Phenotype: Carriers of 1 or 2 copies of the G allele for rs5760410 showed increased risk of any (OR = 3.07, CI 1.22-8.76, p = 0.01) or gastrointestinal-specific (OR = 4.58, CI = 1.01-42.05, p = 0.03) adverse events. Study size: 309 RA patients, including 147 good MTX responders, 101 MTX inefficacy failures, and 61 adverse event (AE) MTX failures (e.g. gastrointestinal (n = 24), abnormal liver function tests (n = 20), haematological (n = 7), skin rashes (n = 6), and other (n = 17). Study population/ethnicity: Rheumatoid arthritis (RA) patients aged over 18 yrs, of White Caucasian ethnic origin, classified as having RA according to ARA criteria that were retrospectively recruited from University Hospital of North Staffordshire (UHNS) and Central Manchester and Manchester Children&apos;s University Hospitals Trust (CMMC) in England. Significance metric(s): OR = 3.07-4.58, p = 0.01-0.03. Type of association: GN; PD; TOX; ADR.
|Drugs=methotrexate
|Drug Classes=
|Diseases=Arthritis, Rheumatoid; Drug Toxicity
|Curation Level=Curated
|PharmGKB Accession ID=PA165110740
}}

{{PharmGKB
|RSID=rs5760410
|Name_s=
|Gene_s=CYTSA
|Feature=
|Evidence=PubMed ID:18256692
|Annotation=SNP is associated with the onset of toxicity to methotrexate in patients with psoriasis.
|Drugs=methotrexate
|Drug Classes=
|Diseases=Psoriasis
|Curation Level=Curated
|PharmGKB Accession ID=PA161149187
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs5760410
|overall_frequency_n=67
|overall_frequency_d=128
|overall_frequency=0.523438
|n_genomes=46
|n_genomes_annotated=0
|n_haplomes=59
|n_articles=2
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Illumina Human 1M}}